Page last updated: 2024-11-04

alpha-methylornithine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alpha-methylornithine: inhibitor of ornithine decarboxylase; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2113
CHEMBL ID36743
SCHEMBL ID574141
MeSH IDM0083909

Synonyms (18)

Synonym
ornithine, 2-methyl
dl-alpha-methylornithine
alpha-methylornithine
alpha-methyl ornithine
CHEMBL36743 ,
2-methylornithine
AKOS006347210
2,5-diamino-2-methylpentanoic acid
2,5-diamino-2-methyl-pentanoic acid
bdbm50028201
48047-94-5
SCHEMBL574141
LNDPCYHWPSQBCA-UHFFFAOYSA-N
2-methylornithine #
712258-42-9
alpha-defluoromethylornithine
DTXSID10963990
a-methyl-dl-ornithine

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"Effects of polyamine (PA) synthesis inhibitors--alpha-difluoromethylornithinchloride (DFMO) and alpha-methylornithinchloride (MO)--separately or in combination with the epidermal growth factor (EGF)--on lysosome-phagosome fusion (P-LF) and F-actin content in murine peritoneal macrophages were studied using fluorescent dye Acridine orange for lysosome labelling, FITC-phalloidin for F-actin, and yeast cells as a target."( [Effect of polyamine synthesis inhibitors separately and in combination with epidermal growth factor on fusion of lysosomes with phagosomes and F-actin level in mouse peritoneal macrophages].
Beliaeva, TN; Bulychev, AG; Leont'eva, EA; Mozhenok, TP, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ornithine decarboxylaseRattus norvegicus (Norway rat)Ki40.00002.70002.70002.7000AID150884
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID150884The apparent dissociation constant for irreversible inhibition of rat liver ornithine decarboxylase (ODC)1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
alpha-(Fluoromethyl)dehydroornithine and alpha-(fluoromethyl)dehydroputrescine analogues as irreversible inhibitors of ornithine decarboxylase.
AID23590Pharmacokinetic parameter half life was determined; No time-dependent inhibition1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
alpha-(Fluoromethyl)dehydroornithine and alpha-(fluoromethyl)dehydroputrescine analogues as irreversible inhibitors of ornithine decarboxylase.
AID22943The times of half-inactivation constant (T50) was determined for ODC; No time-dependent inhibition1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
alpha-(Fluoromethyl)dehydroornithine and alpha-(fluoromethyl)dehydroputrescine analogues as irreversible inhibitors of ornithine decarboxylase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (88.57)18.7374
1990's3 (8.57)18.2507
2000's1 (2.86)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.70 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]